Analysts See $-0.95 EPS for ESSA Pharma Inc. (EPI)

July 14, 2018 - By Nadine Davis

Analysts expect ESSA Pharma Inc. (CVE:EPI) to report $-0.95 EPS on August, 13.They anticipate $3.45 EPS change or 78.41 % from last quarter’s $-4.4 EPS. After having $-1.05 EPS previously, ESSA Pharma Inc.’s analysts see -9.52 % EPS growth. The stock decreased 1.57% or $0.08 during the last trading session, reaching $5. About 500 shares traded. ESSA Pharma Inc. (CVE:EPI) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. The company has market cap of $28.88 million. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: